The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
== Platyhelminthes == Clonorchis sinensis, liver fluke (human pathogen) (draft 2011) Echinococcus granulosus, tapeworm (dog pathogen) (2013, 2013) Echinococcus multilocularis, tapeworm (2013) Hymenolepis microstoma, tapeworm (2013) Schistosoma haematobium, schistosome (human pathogen) (2012 2019) Schistosoma japonicum, schistosome (human pathogen) (2009) Schistosoma mansoni, schistosome (human pathogen) (2009, 2012) Schmidtea mediterranea, planarian (model organism) (2006) Taenia solium, tapeworm (2013)
Calliphoridae (blowflies) Some examples include Calliphora vomitoria, Calliphora vicina, and Cordylobia Oestridae (botflies) Sarcophagidae (fleshflies) Sarcophaga barbata are usually found in dead and rotting meat and animal excrement, which are prime environments for them. This is because their larvae are facultative parasites, as they feed on organic tissue and use the hosts' oxygen reserve. Other families occasionally involved are:
Looking ahead, several challenges are expected to shape foodborne risks. Climate change alters pathogen ecology, expands the geographic range and seasonal windows of hazards, and increases extreme weather events that can contaminate crops and water, raising food safety risks along with food insecurity. Furthermore, antimicrobial resistance (AMR) in foodborne and zoonotic pathogens is another urgent threat that complicates treatment and increases the probability of severe outcomes. As a result, there is a need for integrated AMR action across human, animal, plant, and environmental sectors. Additionally, globalized supply chains, shifts toward ready-to-eat and minimally processed foods, and novel food technologies such as cultivated foods, new packaging, and nanomaterials introduce new risk profiles that require adaptive risk assessment and modernized regulations. Maintaining public trust will also demand transparent risk communication and timely disclosure during outbreaks, particularly in complex societies, paired with investments in laboratory capacity, whole genome sequencing networks, and digital traceability to speed source attribution.
=== Faith and beliefs === When asked if he believed in God, Freeman said: "It's a hard question because as I said at the start, I think we invented God. So if I believe in God, and I do, it's because I think I'm God." He later said that his experience working on The Story of God with Morgan Freeman did not change his views on religion, further stating that he sees Zoroastrianism being a belief system, that, "is intrinsically me: 'Good thoughts, good words, good deeds' sums it up. How many of us that believe in that?".
Sources: en.wikipedia.org
The isotope-ratio mass spectrometer (IRMS) allows the precise measurement of mixtures of naturally occurring isotopes. Most instruments used for precise determination of isotope ratios are of the magnetic sector type. This type of analyzer is superior to the quadrupole type in this field of research for two reasons. First, it can be set up for multiple-collector analysis, and second, it gives high-quality 'peak shapes'. Both of these considerations are important for isotope-ratio analysis at very high precision and accuracy. The sector-type instrument designed by Alfred Nier was such an advance in mass spectrometer design that this type of instrument is often called the 'Nier type'. In the most general terms the instrument operates by ionizing the sample of interest, accelerating it over a potential in the kilo-volt range, and separating the resulting stream of ions according to their mass-to-charge ratio (m/z). Beams with lighter ions bend at a smaller radius than beams with heavier ions. The current of each ion beam is then measured using a 'Faraday cup' or multiplier detector. Many radiogenic isotope measurements are made by ionization of a solid source, whereas stable isotope measurements of light elements (e.g. H, C, O) are usually made in an instrument with a gas source. In a "multicollector" instrument, the ion collector typically has an array of Faraday cups, which allows the simultaneous detection of multiple isotopes.
== Technology == Flagler Global Logistics is using a new, proprietary, single-source, cold chain technology to attract more business from Latin and South American importers of perishable goods. Importers generally use colder northern ports, and then truck the products (which can include fruits, vegetables, and fresh-cut flowers) south in order to protect local farms against fruit flies and other pests. However, this circuitous supply chain route can contribute to large losses in products. Industry reports estimate that $35 billion in perishable foods are lost annually between farm and table, with nearly half of those losses due to in-transit temperature changes. FGL's new facility allows the company to employ a new cold chain process and treatment methods that can extend the shelf life of produce and other perishable items. In December 2013, the USDA approved the Logistics Center's treatment methods. Flagler Global Logistics President and CEO Chris Scott described the USDA approval as a “game-changer” in the industry, because it opens up Miami as a viable alternate distribution hub for Latin America exporters. Flagler Global Logistics also holds certifications from PrimusGFS (Global Food Safety Initiative scheme) and the FDA.
The U.S. Army Special Forces traces its roots as the Army's premier proponent of unconventional warfare from purpose-formed special operations units like the Alamo Scouts, Philippine guerrillas, First Special Service Force, and the Operational Groups (OGs) of the Office of Strategic Services. Although the OSS was not an Army organization, many Army personnel were assigned to the OSS and later used their experiences to influence the forming of Special Forces. During the Korean War, individuals such as former Philippine guerrilla commanders Col. Wendell Fertig and Lt. Col. Russell W. Volckmann used their wartime experience to formulate the doctrine of unconventional warfare that became the cornerstone of the Special Forces. In 1951, Major General Robert A. McClure chose former OSS member Colonel Aaron Bank as Operations Branch Chief of the Special Operations Division of the Psychological Warfare Staff (OCPW) in the Pentagon. In June 1952, the 10th Special Forces Group (Airborne) was formed under Col. Aaron Bank, soon after the establishment of the Psychological Warfare School, which ultimately became today's John F. Kennedy Special Warfare Center and School. The 10th Special Forces Group (Airborne) was split, with the cadre that kept the designation 10th SFG deployed to Bad Tölz, Germany, in September 1953. The remaining cadre at Fort Bragg formed the 77th Special Forces Group, which in May 1960 was reorganized and designated as today's 7th Special Forces Group.
Sources: en.wikipedia.org
Telomerase, also called terminal transferase, is a ribonucleoprotein that adds a species-dependent telomere repeat sequence to the 3' end of telomeres. A telomere is a region of repetitive sequences at each end of the chromosomes of most eukaryotes. Telomeres protect the end of the chromosome from DNA damage or from fusion with neighbouring chromosomes. The fruit fly Drosophila melanogaster lacks telomerase, but instead uses retrotransposons to maintain telomeres. Telomerase is a reverse transcriptase enzyme that carries its own RNA molecule (e.g., with the sequence 3′-CCCAAUCCC-5′ in Trypanosoma brucei) which is used as a template when it elongates telomeres. Telomerase is active in gametes and most cancer cells, but is normally absent in most somatic cells.
1991: Doris Malkin Curtis became the first female president of the Geological Society of America. 1991: Indian geologist Sudipta Sengupta became the first female scientist to receive the Shanti Swaroop Bhatnagar Award in the Earth Sciences category. 1991; British chemist and cosmonaut Helen Patricia Sharman became the first woman to visit the Mir space station in May 1991. 1992: American engineer, physician, and NASA astronaut Mae Carol Jemison became the first black woman to travel into space when she served as a mission specialist aboard the Space Shuttle Endeavour. Jemison joined NASA's astronaut corps in 1987 and was selected to serve for the STS-47 mission, during which she orbited the Earth for nearly eight days on September 12–20, 1992. 1992: American chemist Edith M. Flanigen became the first woman awarded the Perkin Medal (widely considered the highest honor in American industrial chemistry) for her outstanding achievements in applied chemistry. The medal especially recognized her syntheses of aluminophosphate and silicoaluminophosphate molecular sieves as new classes of materials. 1993: American molecular biologist and biogerontologist Cynthia Kenyon discovered that a single-gene mutation (Daf-2) could double the lifespan of C. elegans, and that this could be reversed by a second mutation in daf-16m. 1995: German biologist Christiane Nüsslein-Volhard received the Nobel Prize in Physiology or Medicine, shared with Edward B. Lewis and Eric F. Wieschaus, "for their discoveries concerning the genetic control of early embryonic development".
== Preparation == Field corn grain is dried and then treated by cooking the mature, hard grain in a diluted solution of slaked lime (calcium hydroxide) or wood ash and then letting it soak for many hours. The soaked maize is then rinsed thoroughly to remove the unpalatable flavor of the alkali. This process is nixtamalization, and it produces hominy, which is ground into a relatively dry dough to create fresh masa. The fresh masa can be sold or used directly, or can be dehydrated and blended into a powder to create masa harina, or masa flour. Lime and ash are highly alkaline, which helps the dissolution of hemicellulose, the major glue-like component of the maize cell walls, and loosens the hulls from the kernels and softens the corn. Some of the corn oil is broken down into emulsifying agents (monoglycerides and diglycerides), while bonding of the corn proteins to each other is also facilitated. The divalent calcium in lime acts as a cross-linking agent for protein and polysaccharide acidic side chains. The chemical changes in masa allow dough formation, and also allow the nutrient niacin to be absorbed by the digestive tract. By contrast, untreated cornmeal is unable to form dough on the addition of water, and a diet heavily reliant on its consumption is a risk factor for pellagra.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.